论文部分内容阅读
Alzheimers disease(AD)is a degenerative brain disorder and a major cause of dementia for which no cure is known.The primary approach for treating AD has therefore focused on increasing the levels of acetylcholine in the brain by using acetylcholinest-erase inhibitors(AChEI).c-Jun N-terminal kinases(JNKs),in particular JNK3 has been further implicated as a key player in neurode-generative disorders,including Alzheimers disease[1].